Eli Lilly's Alzheimer's Disease Medication Approved by FDA
July 3, 2024 4:01 JST
Long-awaited approval for “donanemab AZBT” after more than 3 years of procedures
The United States, which has 6 million patients, is the second most approved after Eisai's “Recembi”
An Alzheimer's disease treatment drug developed by US pharmaceutical giant Eli Lilly has been approved in the US. It received approval from the U.S. Food and Drug Administration (FDA) for the second time as a drug that delays the progression of symptoms in 6 million patients in the United States.
It was over 3 years ago that “donanemab AZBT (kisunla)” showed effects in clinical trials. The approval, which was obtained after numerous delays in regulatory procedures, was a big win for Lily and investors. It competes with Eisai's “Rekenbi,” which was approved for sale in the US in early 2023.
Long-awaited approval for “donanemab AZBT” after more than 3 years of procedures
The United States, which has 6 million patients, is the second most approved after Eisai's “Recembi”
An Alzheimer's disease treatment drug developed by US pharmaceutical giant Eli Lilly has been approved in the US. It received approval from the U.S. Food and Drug Administration (FDA) for the second time as a drug that delays the progression of symptoms in 6 million patients in the United States.
It was over 3 years ago that “donanemab AZBT (kisunla)” showed effects in clinical trials. The approval, which was obtained after numerous delays in regulatory procedures, was a big win for Lily and investors. It competes with Eisai's “Rekenbi,” which was approved for sale in the US in early 2023.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
